This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RedHill Biopharma Reports Positive PK Results In Support Of Ongoing RHB-105 Phase III H. Pylori Study

  • The positive results from the pharmacokinetic study support the continuation of the ERADICATE Hp study - a Phase III clinical study currently underway in the U.S., evaluating RHB-105 as a first-line therapy for H. pylori bacterial infection
  • The objectives of the PK study were to evaluate RHB-105's pharmacokinetics and bioavailability properties, and to assess safety
  • RedHill recently announced that the first patients have been dosed in the ERADICATE Hp Phase III study, with data expected by the third quarter of 2014

TEL-AVIV, Israel, Dec. 23, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late stage, proprietary formulations and combinations of existing drugs, today reported positive results from a pharmacokinetic (PK) study with RHB-105, a proprietary combination therapy, oral capsule formulation, for eradication of Helicobacter pylori ( H. pylori) infection, a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (MALT) lymphoma.

The results of the PK study, including the pharmacokinetics, bioavailability and safety of RHB-105, are subject to final quality assurance and an independent study report by the Canadian clinical research organization (CRO) which conducted the study. The final independent report from the CRO is expected in the coming weeks.

The objective of the randomized open-label, 2-arm crossover PK study was to evaluate the pharmacokinetics and bioavailability of the RHB-105 all-in-one oral capsule and compare those to the concomitant administration of the three individual active drugs comprising RHB-105. The secondary objective of the PK study was to assess the safety of the RHB-105 combination formulation in healthy volunteers.

The positive results of the PK study provide support for the continuation of the RHB-105 ERADICATE Hp Phase III study that is currently underway in the U.S.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $103.59 2.60%
GOOG $687.99 0.57%
TSLA $151.64 5.50%
YHOO $27.09 -0.04%


Chart of I:DJI
DOW 15,762.57 +102.39 0.65%
S&P 500 1,842.49 +13.41 0.73%
NASDAQ 4,306.4130 +39.5760 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs